Evidenced-based clinical practice guideline for upper tract urothelial carcinoma (summary - Japanese Urological Association, 2014 edition)

International Journal of Urology

Volumn 22, Issue 1, 2015, Pages 3-13

  Oya, Mototsugu ^a   Kikuchi, Eiji ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Guideline; Renal pelvic tumor; Upper tract urothelial carcinoma; Ureteral tumor

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL PRACTICE; COMPUTED TOMOGRAPHIC UROGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISTANT METASTASIS; DRUG INSTILLATION; EVIDENCE BASED PRACTICE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; KIDNEY SPARING SURGERY; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); NEPHROURETERECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADICAL NEPHROURETERECTOMY WITH BLADDER CUFF EXCISION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROGRADE PYELOGRAPHY; RISK FACTOR; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW (TOPIC); TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URETEROSCOPY; URINE CYTOLOGY; UROGRAPHY; CARCINOMA, TRANSITIONAL CELL; EVIDENCE BASED MEDICINE; JAPAN; KIDNEY PELVIS; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PROGNOSIS; QUESTIONNAIRE; URETERAL NEOPLASMS; UROLOGY;

CARCINOMA, TRANSITIONAL CELL; EVIDENCE-BASED MEDICINE; HUMANS; JAPAN; KIDNEY PELVIS; PROGNOSIS; QUESTIONNAIRES; SOCIETIES, MEDICAL; URETERAL NEOPLASMS; UROLOGY;

EID: 84920895447     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12630     Document Type: Article

References (113)

1. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 1988; 62: 2016-2020.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J. Clin. 2000; 50: 7-33.
3. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998; 52: 594-601.
4. McLaughlin JK, Silverman DT, Hsing AW etal. Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res. 1992; 52: 254-257.
5. Brenner DW, Schellhammer PF. Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review. J. Urol. 1987; 137: 1226-1227.
6. McCredie M, Stewart JH, Carter JJ, Turner J, Mahony JF. Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer. Kidney Int. 1986; 30: 81-84.
7. Grollman AP, Shibutani S, Moriya M etal. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 12129-12134.
8. Nortier JL, Martinez MC, Schmeiser HH etal. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 2000; 342: 1686-1692.
9. Hagiwara M, Kikuchi E, Tanaka N etal. Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. J. Urol. 2013; 189: 2062-2068.
10. Milojevic B, Djokic M, Sipetic-Grujicic S etal. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Urol. Oncol. 2013; 31: 1615-1620.
11. Raman JD, Ng CK, Boorjian SA, Vaughan ED Jr, Sosa RE, Scherr DS. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int. 2005; 96: 1031-1035.
12. Hirano D, Okada Y, Nagane Y etal. Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract. Urol. Int. 2012; 89: 71-77.
13. Takaoka E, Hinotsu S, Joraku A etal. Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int. J. Urol. 2010; 17: 623-628.
14. Habuchi T. Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. Int. J. Urol. 2005; 12: 709-716.
15. Miyake H, Hara I, Kamidono S, Eto H. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J. Urol. 2004; 172: 1127-1129.
16. Jinzaki M, Matsumoto K, Kikuchi E etal. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am. J. Roentgenol. 2011; 196: 1102-1109.
17. Wang LJ, Wong YC, Huang CC, Wu CH, Hung SC, Chen HW. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J. Urol. 2010; 183: 48-55.
18. Cowan NC, Turney BW, Taylor NJ, McCarthy CL, Crew JP. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int. 2007; 99: 1363-1370.
19. Fritz GA, Schoellnast H, Deutschmann HA, Quehenberger F, Tillich M. Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract. Eur. Radiol. 2006; 16: 1244-1252.
20. Takahashi N, Glockner JF, Hartman RP etal. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J. Urol. 2010; 183: 1330-1365.
21. Takahashi N, Kawashima A, Glockner JF etal. Small (<2-cm) upper-tract urothelial carcinoma: evaluation with gadolinium-enhanced three-dimensional spoiled gradient-recalled echo MR urography. Radiology 2008; 247: 451-457.
22. Thomsen HS, European Society of Urogenital R. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur. Radiol. 2007; 17: 2692-2696.
23. Akita H, Jinzaki M, Kikuchi E etal. Preoperative T categorization and prediction of histopathologic grading of urothelial carcinoma in renal pelvis using diffusion-weighted MRI. AJR Am. J. Roentgenol. 2011; 197: 1130-1136.
24. Yoshida S, Kobayashi S, Koga F etal. Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report. Eur. Radiol. 2013; 23: 2206-2214.
25. Messer J, Shariat SF, Brien JC etal. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011; 108: 701-705.
26. Renshaw AA. Comparison of ureteral washing and biopsy specimens in the community setting. Cancer 2006; 108: 45-48.
27. Williams SK, Denton KJ, Minervini A etal. Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. J. Endourol. 2008; 22: 71-76.
28. Sedlock DJ, MacLennan GT. Urine cytology in the evaluation of upper tract urothelial lesions. J. Urol. 2004; 172: 2406.
29. Highman WJ. Transitional carcinoma of the upper urinary tract: a histological and cytopathological study. J. Clin. Pathol. 1986; 39: 297-305.
30. Guarnizo E, Pavlovich CP, Seiba M, Carlson DL, Vaughan ED Jr, Sosa RE. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J. Urol. 2000; 163: 52-55.
31. Clements T, Messer JC, Terrell JD etal. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J. Endourol. 2012; 26: 398-402.
32. Margulis V, Youssef RF, Karakiewicz PI etal. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J. Urol. 2010; 184: 453-458.
33. Favaretto RL, Shariat SF, Savage C etal. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int. 2012; 109: 77-82.
34. Brien JC, Shariat SF, Herman MP etal. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J. Urol. 2010; 184: 69-73.
35. Eng MK, Shalhav AL. Laparoscopic nephroureterectomy: long-term outcomes. Curr. Opin. Urol. 2008; 18: 157-162.
36. Rassweiler JJ, Schulze M, Marrero R, Frede T, Palou Redorta J, Bassi P. Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery? Eur. Urol. 2004; 46: 690-697.
37. Simone G, Papalia R, Guaglianone S etal. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur. Urol. 2009; 56: 520-526.
38. Kondo T, Hashimoto Y, Kobayashi H etal. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. Int. J. Urol. 2010; 17: 848-854.
39. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J. Urol. 2007; 178: 1212-1217.
40. Abe T, Shinohara N, Muranaka M etal. Role of lymph node dissection in the treatment of urothelial carcinoma of the upper urinary tract: multi-institutional relapse analysis and immunohistochemical re-evaluation of negative lymph nodes. Eur. J. Surg. Oncol. 2010; 36: 1085-1091.
41. Roscigno M, Cozzarini C, Bertini R etal. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur. Urol. 2008; 53: 794-802.
42. Roscigno M, Shariat SF, Margulis V etal. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur. Urol. 2009; 56: 512-518.
43. Burger M, Shariat SF, Fritsche HM etal. No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. World J. Urol. 2011; 29: 465-472.
44. Lughezzani G, Jeldres C, Isbarn H etal. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2010; 75: 118-124.
45. Ritch CR, Kearns JT, Mues AC etal. Comparison of distal ureteral management strategies during laparoscopic nephroureterectomy. J. Endourol. 2011; 25: 1149-1154.
46. Xylinas E, Rink M, Cha EK etal. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur. Urol. 2014; 65: 210-217.
47. Hattori R, Yoshino Y, Gotoh M, Katoh M, Kamihira O, Ono Y. Laparoscopic nephroureterectomy for transitional cell carcinoma of renal pelvis and ureter: Nagoya experience. Urology 2006; 67: 701-705.
48. Li WM, Shen JT, Li CC etal. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur. Urol. 2010; 57: 963-969.
49. Gkougkousis EG, Mellon JK, Griffiths TR. Management of the distal ureter during nephroureterectomy for upper urinary tract transitional cell carcinoma: a review. Urol. Int. 2010; 85: 249-256.
50. Matin SF, Gill IS. Recurrence and survival following laparoscopic radical nephroureterectomy with various forms of bladder cuff control. J. Urol. 2005; 173: 395-400.
51. Giovansili B, Peyromaure M, Saighi D, Dayma T, Zerbib M, Debre B. Stripping technique for endoscopic management of distal ureter during nephroureterectomy: experience of 32 procedures. Urology 2004; 64: 448-452.
52. Karam JA, Margulis V, Montorsi F etal. Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy-results from a multicenter study. Eur. Urol. 2008; 54: 961-963.
53. Kojima Y, Tozawa K, Kawai N, Sasaki S, Hayashi Y, Kohri K. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guerin therapy. Int. J. Urol. 2006; 13: 340-344.
54. Bamias A, Deliveliotis C, Fountzilas G etal. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 2004; 22: 2150-2154.
55. Soga N, Arima K, Sugimura Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int. J. Urol. 2008; 15: 800-803.
56. Hellenthal NJ, Shariat SF, Margulis V etal. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J. Urol. 2009; 182: 900-906.
57. Alva AS, Matin SF, Lerner SP, Siefker-Radtke AO. Perioperative chemotherapy for upper tract urothelial cancer. Nat. Rev. Urol. 2012; 9: 266-273.
58. Matin SF, Margulis V, Kamat A etal. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010; 116: 3127-3134.
59. Rajput MZ, Kamat AM, Clavell-Hernandez J etal. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 2011; 78: 61-67.
60. Margulis V, Shariat SF, Matin SF etal. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224-1233.
61. Rink M, Sjoberg D, Comploj E etal. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann. Surg. Oncol. 2012; 19: 4337-4344.
62. Azemar MD, Comperat E, Richard F, Cussenot O, Roupret M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol. Oncol. 2011; 29: 130-136.
63. Shariat SF, Godoy G, Lotan Y etal. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int. 2010; 105: 1672-1677.
64. Fernandez MI, Shariat SF, Margulis V etal. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology 2009; 73: 142-146.
65. Raman JD, Shariat SF, Karakiewicz PI etal. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol. Oncol. 2011; 29: 716-723.
66. Rink M, Xylinas E, Margulis V etal. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur. Urol. 2013; 63: 1082-1090.
67. Ouzzane A, Colin P, Xylinas E etal. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur. Urol. 2011; 60: 1258-1265.
68. Raman JD, Ng CK, Scherr DS etal. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur. Urol. 2010; 57: 1072-1079.
69. Ito Y, Kikuchi E, Tanaka N etal. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J. Urol. 2011; 185: 1621-1626.
70. Brown GA, Matin SF, Busby JE etal. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 2007; 70: 252-256.
71. Ng CK, Shariat SF, Lucas SM etal. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? Urol. Oncol. 2011; 29: 27-32.
72. Li CC, Chang TH, Wu WJ etal. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur. Urol. 2008; 54: 1127-1134.
73. Novara G, De Marco V, Gottardo F etal. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer 2007; 110: 1715-1722.
74. Lughezzani G, Jeldres C, Isbarn H etal. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur. J. Cancer 2009; 45: 3291-3297.
75. Bolenz C, Shariat SF, Fernandez MI etal. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int. 2009; 103: 302-306.
76. Wheat JC, Weizer AZ, Wolf JS Jr etal. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol. Oncol. 2012; 30: 252-258.
77. Kikuchi E, Margulis V, Karakiewicz PI etal. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J. Clin. Oncol. 2009; 27: 612-618.
78. Novara G, Matsumoto K, Kassouf W etal. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur. Urol. 2010; 57: 1064-1071.
79. Chromecki TF, Cha EK, Fajkovic H etal. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur. Urol. 2012; 61: 245-253.
80. Simone G, Papalia R, Loreto A, Leonardo C, Sentinelli S, Gallucci M. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma. BJU Int. 2009; 103: 1052-1057.
81. Shariat SF, Zigeuner R, Rink M etal. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification. Eur. Urol. 2012; 62: 224-231.
82. Yoshimura K, Arai Y, Fujimoto H etal. Prognostic impact of extensive parenchymal invasion pattern in pT3 renal pelvic transitional cell carcinoma. Cancer 2002; 94: 3150-3156.
83. Capitanio U, Shariat SF, Isbarn H etal. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur. Urol. 2009; 56: 1-9.
84. Roscigno M, Shariat SF, Margulis V etal. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J. Urol. 2009; 181: 2482-2489.
85. Cha EK, Shariat SF, Kormaksson M etal. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur. Urol. 2012; 61: 818-825.
86. Matsui Y, Utsunomiya N, Ichioka K etal. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005; 65: 279-283.
87. Terakawa T, Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology 2008; 71: 123-127.
88. Novara G, De Marco V, Dalpiaz O etal. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int. 2008; 101: 1368-1374.
89. Pieras E, Frontera G, Ruiz X, Vicens A, Ozonas M, Piza P. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. BJU Int. 2010; 106: 1319-1323.
90. Huang WW, Huang HY, Liao AC etal. Primary urothelial carcinoma of the upper tract: important clinicopathological factors predicting bladder recurrence after surgical resection. Pathol. Int. 2009; 59: 642-649.
91. Kusuda Y, Miyake H, Terakawa T, Kondo Y, Miura T, Fujisawa M. Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. Urol. Oncol. 2013; 31: 899-903.
92. Manabe D, Saika T, Ebara S etal. Comparative study of oncologic outcome of laparoscopic nephroureterectomy and standard nephroureterectomy for upper urinary tract transitional cell carcinoma. Urology 2007; 69: 457-461.
93. O'Brien T, Ray E, Singh R, Coker B, Beard R. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur. Urol. 2011; 60: 703-710.
94. Ito A, Shintaku I, Satoh M etal. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J. Clin. Oncol. 2013; 31: 1422-1427.
95. Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012; 110: 614-628.
96. Cutress ML, Stewart GD, Wells-Cole S, Phipps S, Thomas BG, Tolley DA. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int. 2012; 110: 1608-1617.
97. Iborra I, Solsona E, Casanova J, Ricos JV, Rubio J, Climent MA. Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J. Urol. 2003; 169: 82-85.
98. Keeley FX Jr, Bibbo M, Bagley DH. Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J. Urol. 1997; 157: 1560-1565.
99. Suh RS, Faerber GJ, Wolf JS Jr. Predictive factors for applicability and success with endoscopic treatment of upper tract urothelial carcinoma. J. Urol. 2003; 170: 2209-2216.
100. Palou J, Piovesan LF, Huguet J, Salvador J, Vicente J, Villavicencio H. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J. Urol. 2004; 172: 66-69.
101. Tanji N, Ozawa A, Miura N etal. Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. Int. J. Clin. Oncol. 2010; 15: 369-375.
102. Audenet F, Yates DR, Cussenot O, Roupret M. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol. Oncol. 2013; 31: 407-413.
103. Lane BR, Smith AK, Larson BT etal. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 2010; 116: 2967-2973.
104. Tanaka N, Kikuchi E, Kanao K etal. Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions. BJU Int. 2013; 112: E28-34.
105. Cho KS, Joung JY, Seo HK etal. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract. Cancer Chemother. Pharmacol. 2011; 67: 769-774.
106. Giannarini G, Kessler TM, Birkhauser FD, Thalmann GN, Studer UE. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur. Urol. 2011; 60: 955-960.
107. Keeley FX Jr, Bagley DH. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J. Urol. 1997; 158: 2074-2077.
108. Martinez-Pineiro JA, Garcia Matres MJ, Martinez-Pineiro L. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J. Urol. 1996; 156: 377-385.
109. Rastinehad AR, Ost MC, Vanderbrink BA etal. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy? Urology 2009; 73: 27-31.
110. Chen B, Zeng ZC, Wang GM etal. Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. BMC Cancer 2011; 11: 297.
111. Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J. Urol. 2004; 172: 1271-1275.
112. Hall MC, Womack JS, Roehrborn CG, Carmody T, Sagalowsky AI. Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. J. Urol. 1998; 160: 703-706.
113. Maulard-Durdux C, Dufour B, Hennequin C etal. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival? J. Urol. 1996; 155: 115-117.